Today: 21 May 2026
Browse Category

NASDAQ:DAVE 4 November 2025 - 14 January 2026

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc (DAVE.O) shares fell 8.8% to $218.29 Monday after President Trump called for a 10% cap on credit card interest rates, sparking a selloff in credit-sensitive stocks. About 1.1 million Dave shares traded by mid-afternoon. The drop mirrored declines in other fintechs, including Upstart and Affirm. Dave also faces a Justice Department complaint alleging it misled users about fees, which the company disputes.
12 January 2026
··
Dave Inc Stock (DAVE) Today: Price, Latest News, Analyst Targets, and What to Watch as Wall Street Trades the Post‑Christmas Rally

Dave Inc Stock (DAVE) Today: Price, Latest News, Analyst Targets, and What to Watch as Wall Street Trades the Post‑Christmas Rally

Dave Inc. shares traded near $227.45, down 0.5% Friday morning, amid light post-Christmas volume. The S&P 500 hovered about 1% below 7,000 as investors watched for signals on 2026 Fed rate cuts. Dave’s Q3 report last month showed revenue up 63% to $150.8 million and net income of $92 million. Broader markets remained steady in quiet holiday trading.
26 December 2025
·
Dave Inc. (DAVE) Stock – Fintech Underdog Turned Wall Street Rocket

Dave Inc. (DAVE) Stock – Fintech Underdog Turned Wall Street Rocket

Dave Inc. stock surged nearly 10% to $264 on November 4 after posting record Q3 revenue of $150.8 million and net income of $92 million. Shares have soared about 500% in the past year, far outpacing the S&P 500. The stock trades near its 52-week high of $286.45, with volatility high and roughly 16% of its float sold short. Most analysts rate DAVE a Buy, with a consensus target of $274.
4 November 2025
·

Stock Market Today

  • Stock Market Today: Key Insights for May 21 Trading
    May 20, 2026, 10:27 PM EDT. Stocks in the news and major brokerage calls shape market sentiment as traders prepare for May 21. This report provides a complete trade setup, highlighting critical market movements and strategies. Stay informed with the essential data before entering trades today.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop